SBUX Research Update — August 28, 2026
Updated Thesis
Starbucks operates a global premium coffeehouse, licensing, digital loyalty and consumer packaged-goods platform, with 41,304 stores across 90 markets, a powerful brand and meaningful licensed-store economics, but its fundamentals remain in a turnaround rather than a fully normalized state. Business quality is medium: global comparable sales rose 7.9% in fiscal Q3 2026 and North America comparable sales rose 8.1%, yet reported revenue declined 1.4% year over year in the most recent quarter because of China deconsolidation, while leverage remains high at $13.38 billion of long-term debt and shareholders' equity was negative $7.67 billion. At $107.26, the shares trade at 3.2x sales, 61.88x trailing earnings, 33.68x free cash flow and 24.06x EV/EBITDA despite TTM operating and net margins of 9.4% and 5.2%, respectively.
The investment grade as of this refresh is C — average business quality. Medium-tier business, expensive-tier valuation; 16.8% downside to $89.21 fair value.
Grade Change
In this research cycle, the investment grade for Starbucks Corporation moved from D to C. Medium-tier business, expensive-tier valuation; 16.8% downside to $89.21 fair value.
Key Metrics at a Glance
- Revenue growth: -1.4% year over year
- Net margin: 5.2%
- Fair value upside: -16.8% to our estimate of $89
Current price: $107.26
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Starbucks Corporation remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full SBUX research →](/stocks/SBUX)